Maksymilian Swiniarski is a leader with extensive experience in business and project management. For more than 20 years he has been associated with the pharmaceutical industry - he worked in the largest biotechnology corporations in the world, where he held key positions and gained the knowledge and skills necessary to manage a dynamically growing company such as TZF Polfa. In the structures of such companies as BAYER, Eli Lilly Poland, AstraZeneca and Synthaverse, he was responsible for drug launches and successfully implemented the strategy for the development of products in the fields of diabetology, oncology, cardiology and psychiatry.
Under the leadership of Maksymilian Swiniarski, the Company intends to continue the investments it has started.
"I am extremely pleased to join the TZF Polfa team at such an exceptional time. The year 2024 marks the beginning of TZF Polfa's third centenary year, which I am convinced will bring a significant acceleration of development. The main goal in the near future is to launch the Oncology Drug Development and Production Center, which is crucial for the Polish healthcare system and drug safety," Maksymilian Swiniarski said.
TZF Polfa recently obtained an occupancy permit for the building and is implementing the next stages of the investment, which includes qualification of the technological part of the facility.
"The commercialization of new drugs will be a significant event, positively influencing the safety, but most importantly the health of patients. I would like to emphasize that this is a unique project, also on a European scale. At this point, I would like to thank the tremendous commitment of the entire team dedicated to the implementation of this and other projects. The project is being implemented as planned, and other strategic projects, increasing production capacity and new drug registrations and introductions will accelerate the Company's development," Maksymilian Swiniarski said.
TZF Polfa is a company for which one of its priorities is to ensure national drug safety by maintaining the availability of key medicinal products regardless of the geopolitical situation. The new president aims to further develop and strengthen TZF Polfa's market position on both the domestic and international markets.
"The current excellent relationships with partners in Poland and abroad, as well as our activity in the international arena, will help increase the Company's market share and importance in the Polish healthcare system. This is a great task, but above all a responsibility for patients. I am convinced that together with such an experienced team we will achieve the goals set before us." - Maksymilian Swiniarski concluded.
Source: MediaRoom PAP
